[go: up one dir, main page]

ZA887362B - Dosage form for treating cardiovascular diseases - Google Patents

Dosage form for treating cardiovascular diseases

Info

Publication number
ZA887362B
ZA887362B ZA887362A ZA887362A ZA887362B ZA 887362 B ZA887362 B ZA 887362B ZA 887362 A ZA887362 A ZA 887362A ZA 887362 A ZA887362 A ZA 887362A ZA 887362 B ZA887362 B ZA 887362B
Authority
ZA
South Africa
Prior art keywords
dosage form
cardiovascular diseases
treating cardiovascular
treating
diseases
Prior art date
Application number
ZA887362A
Other languages
English (en)
Inventor
Atul Davdatt Ayer
Davdatt Ayer Atul
David R Swanson
R Swanson David
Anthony L Kuczynski
L Kuczynski Anthony
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ZA887362B publication Critical patent/ZA887362B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA887362A 1987-10-02 1988-09-30 Dosage form for treating cardiovascular diseases ZA887362B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/104,006 US4816263A (en) 1987-10-02 1987-10-02 Dosage form for treating cardiovascular diseases comprising isradipine

Publications (1)

Publication Number Publication Date
ZA887362B true ZA887362B (en) 1989-06-28

Family

ID=22298196

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA887362A ZA887362B (en) 1987-10-02 1988-09-30 Dosage form for treating cardiovascular diseases

Country Status (22)

Country Link
US (1) US4816263A (pt)
JP (1) JP2590235B2 (pt)
KR (1) KR950010151B1 (pt)
AT (1) AT402689B (pt)
AU (1) AU615215B2 (pt)
BE (1) BE1001101A5 (pt)
CA (1) CA1317550C (pt)
CH (1) CH677609A5 (pt)
DE (1) DE3833282C2 (pt)
DK (1) DK175564B1 (pt)
ES (1) ES2011120A6 (pt)
FI (1) FI92554C (pt)
FR (1) FR2622798B1 (pt)
GB (1) GB2210266B (pt)
IE (1) IE61862B1 (pt)
IT (1) IT1234215B (pt)
LU (1) LU87351A1 (pt)
NL (1) NL194748C (pt)
NO (1) NO176466C (pt)
PT (1) PT88618B (pt)
SE (1) SE503471C2 (pt)
ZA (1) ZA887362B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
MXPA03011565A (es) * 2001-06-11 2004-10-28 Xenoport Inc Profarmacos de analogos de gaba, composiciones y usos de las mismas.
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
AU2002345638A1 (en) * 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
WO2004052841A1 (en) 2002-12-06 2004-06-24 Xenoport, Inc. Carbidopa prodrugs and uses thereof
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
NZ543138A (en) * 2003-03-31 2009-02-28 Xenoport Inc Treating or preventing hot flashes using prodrugs of GABA analogs
MXPA06001876A (es) * 2003-08-20 2006-05-17 Xenoport Inc Prodrogas de aciloxialquil carbamato, metodos de sintesis y uso.
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
EP1670451A4 (en) * 2003-09-11 2009-10-21 Xenoport Inc TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
US8114909B2 (en) * 2003-09-17 2012-02-14 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of GABA analogs
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
CA2584338C (en) * 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
CA2612292C (en) 2005-06-20 2013-09-03 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
WO2007027476A2 (en) * 2005-08-26 2007-03-08 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
JP5371746B2 (ja) 2006-05-26 2013-12-18 ファーマコフォア， インコーポレイテッド フェノール性オピオイドの制御放出
US7585996B2 (en) * 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
BRPI0720252A2 (pt) * 2006-12-08 2014-01-07 Xenoport Inc Uso de pró-fármacos de análogos de gaba para tratar doenças
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2011028234A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
CN107050456B (zh) 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
CN102349880B (zh) * 2011-10-12 2015-07-22 合肥华方医药科技有限公司 伊拉地平控释片及其制备方法
CN105030726A (zh) * 2015-08-30 2015-11-11 四川百利药业有限责任公司 一种伊拉地平胶囊的制备方法
GB2556817B (en) 2015-10-01 2019-11-06 Elysium Therapeutics Inc Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
EP3595663A4 (en) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTI-UNIT OPIOID MEDICINES RESISTANT TO OVERDOSE AND ABUSE

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB2181053B (en) * 1985-10-01 1990-05-23 Sandoz Ltd Pharmaceutical formulations with controlled release of the active substance
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
AU2152888A (en) * 1987-08-25 1989-03-02 Cerra Metal Works Pty. Ltd. Masonry tie
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine

Also Published As

Publication number Publication date
NO884259D0 (no) 1988-09-27
CH677609A5 (pt) 1991-06-14
GB8822852D0 (en) 1988-11-02
DE3833282C2 (de) 1997-02-13
NL194748B (nl) 2002-10-01
IT1234215B (it) 1992-05-06
KR890006218A (ko) 1989-06-12
AU615215B2 (en) 1991-09-26
NO884259L (no) 1989-04-03
JPH01113316A (ja) 1989-05-02
CA1317550C (en) 1993-05-11
SE8803486L (sv) 1989-04-03
IE882960L (en) 1989-04-02
GB2210266B (en) 1991-07-24
FR2622798A1 (fr) 1989-05-12
PT88618A (pt) 1989-07-31
NL8802401A (nl) 1989-05-01
SE503471C2 (sv) 1996-06-24
FI884526A (fi) 1989-04-03
IT8867880A0 (it) 1988-09-30
KR950010151B1 (ko) 1995-09-11
FI92554C (fi) 1994-12-12
ATA242288A (de) 1996-12-15
PT88618B (pt) 1993-07-30
JP2590235B2 (ja) 1997-03-12
LU87351A1 (fr) 1989-04-06
AU2293888A (en) 1989-04-06
DE3833282A1 (de) 1989-04-20
NO176466C (no) 1995-04-12
NO176466B (no) 1995-01-02
FR2622798B1 (fr) 1993-10-15
DK545088A (da) 1989-04-03
ES2011120A6 (es) 1989-12-16
GB2210266A (en) 1989-06-07
DK545088D0 (da) 1988-09-29
NL194748C (nl) 2003-02-04
FI92554B (fi) 1994-08-31
FI884526A0 (fi) 1988-09-30
DK175564B1 (da) 2004-12-06
SE8803486D0 (sv) 1988-09-30
US4816263A (en) 1989-03-28
BE1001101A5 (fr) 1989-07-11
IE61862B1 (en) 1994-11-30
AT402689B (de) 1997-07-25

Similar Documents

Publication Publication Date Title
ZA887362B (en) Dosage form for treating cardiovascular diseases
ZA86276B (en) Process for treating dosage forms
GB8719367D0 (en) Therapeutic compounds
GB8725939D0 (en) Therapeutic compounds
GB8724564D0 (en) Therapeutic compounds
IE853321L (en) Process for treating dosage forms
ZA89125B (en) Product treatment
GB8721489D0 (en) Treatment
GB8726981D0 (en) Treatment
GB8712248D0 (en) Treatment
GB8715944D0 (en) Treatment
GB8716536D0 (en) Treatment
GB8708042D0 (en) Treatment
GB8709875D0 (en) Treatment
GB8711457D0 (en) Treatment
GB8712238D0 (en) Treatment
GB8712239D0 (en) Treatment
GB8712242D0 (en) Treatment
GB8712243D0 (en) Treatment
GB8712244D0 (en) Treatment
GB8712245D0 (en) Treatment
GB8712247D0 (en) Treatment
GB8715943D0 (en) Treatment
GB8716533D0 (en) Treatment
GB8716534D0 (en) Treatment